GRAYZEL DAVID S. 4
4 · Aerovate Therapeutics, Inc. · Filed Jun 8, 2023
Insider Transaction Report
Form 4
GRAYZEL DAVID S.
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-06-06+12,500→ 12,500 totalExercise: $16.30Exp: 2033-06-05→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.